... in type 2 diabetic patients [ 1 ]. T2DM may be considered as a specific and independent risk factor for various forms of cancer, due to its particular metabolic characteristics of glucose intolerance and hyperinsulinemia [ 1, 2 ]. Uro-oncology Pathological outcomes Diabetes Metformin...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Renal cell cancer Diabetes Metformin...

...Markus Krebs; Mischa J. Kotlyar; Julian Fahl; Sudha Janaki Raman; Florian Röhrig; André Marquardt; Hubert Kübler; Burkhard Kneitz; Almut Schulze; Charis Kalogirou Introduction: Metformin (MF) intake could be associated with a favorable outcome in sunitinib (SUT)- and axitinib (AX)-treated clear...

...Wenhui Zhu; Hua Xu; Jing Ma; Jianming Guo; Wei Xue; Baojun Gu; Lu Sheng; Xudong Yao; Fukang Sun; Jian Gong; Weiliang Qiu; Qiang Ding; Haowen Jiang Purpose: The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation...

...Charis Kalogirou; Daniel Schäfer; Markus Krebs; Florian Kurz; Andreas Schneider; Hubertus Riedmiller; Burkhard Kneitz; Daniel Vergho Purpose: Metformin (MF) acts as a tumour-suppressor in renal cell carcinoma (RCC) by inhibiting the AKT / mTOR pathway via AMPK activation. Here, we explore...